Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor

Details for Australian Patent Application No. 2009319048 (hide)

Owner Novartis AG

Inventors Garcia-Echeverria, Carlos; Jensen, Michael Rugaard

Agent Davies Collison Cave

Pub. Number AU-A-2009319048

PCT Pub. Number WO2010/060937

Priority 08170279.7 28.11.08 EP; 08170287.0 28.11.08 EP; 08170230.0 28.11.08 EP; 08170246.6 28.11.08 EP

Filing date 25 November 2009

Wipo publication date 3 June 2010

International Classifications

A61K 31/436 (2006.01)

A61K 31/5377 (2006.01)

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

30 June 2011 PCT application entered the National Phase

  PCT publication WO2010/060937 Priority application(s): WO2010/060937

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009319050-Pharmaceutical combinations comprising a pyrido [4, 3-d] pyrimidine derived Hsp90-inhibitor and a HER2 inhibitor

2009319038-Counting and measurement point system for measuring and counting electrical energy and method